Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?
Sohum ShethMaciej BanachPeter P TothPublished in: Expert review of cardiovascular therapy (2024)
There is an urgent need to rethink dyslipidemia management. Opportunities exist to overcome LDL-C goal attainment barriers, which necessitates a concerted effort from patients, clinicians, health systems, payors, pharmaceutical companies, and public health advocates. LDL-C measurement should be a performance metric for health systems. In addition, upfront use of combination therapy and polypill formulations should be encouraged. Engaging pharmacists to support drug therapy and adherence is crucial. Leveraging telehealth and electronic medical record (EMR) functionalities can enhance these efforts and ensure more effective implementation.
Keyphrases
- combination therapy
- public health
- clinical practice
- end stage renal disease
- ejection fraction
- chronic kidney disease
- primary care
- quality improvement
- palliative care
- prognostic factors
- type diabetes
- adipose tissue
- metabolic syndrome
- patient reported outcomes
- low density lipoprotein
- mesenchymal stem cells
- glycemic control
- electronic health record